up-to-date with a click!
Update December, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications December 2017

Other

  1. Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. American journal of obstetrics and gynecology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29229321
  2. Worthington HC, Cheng L, Majumdar SR et al. The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis. Implement Sci 2017; 12:141. http://www.ncbi.nlm.nih.gov/pubmed/?term=29178960

Add on treatments

  1. Scicali R, Di Pino A, Ferrara V et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260404
  2. Issa OM, Roberts R, Mark DB et al. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). Am Heart J 2018; 195:70-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224648
  3. Hibi K, Sonoda S, Kawasaki M et al. Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29212965
  4. Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29263150
  5. Kim CH, Han KA, Yu J et al. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-Treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223557
  6. Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug design, development and therapy 2017; 11:3461-3469. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255347
  7. Weisshaar S, Litschauer B, Kerbel T, Wolzt M. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288055
  8. Menzin J, Aggarwal J, Boatman B et al. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of managed care & specialty pharmacy 2017; 23:1270-1276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172973
  9. Semenova AE, Sergienko IV. [Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease]. Kardiologiia 2017; 57:73-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=29276932
  10. Raffoul-Orozco AK, Avila-Gonzalez AE, Rodriguez-Razon CM et al. Combination effect naringin and pravastatin in lipid profile and glucose in obese rats. Life sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197498
  11. Naiqiong W, Liansheng W, Zhanying H et al. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Medical science monitor : international medical journal of experimental and clinical research 2017; 23:5760-5766. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200411
  12. Sadighara M, Joktaji JP, Hajhashemi V, Minaiyan M. Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Research in pharmaceutical sciences 2017; 12:434-443. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204172

Adherence

  1. Go AS, Fan D, Sung SH et al. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. Am Heart J 2017; 194:25-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223433
  2. Kriegbaum M, Lau SR. Medication non-adherence and uncertainty: Information-seeking and processing in the Danish LIFESTAT survey. Research in social & administrative pharmacy : RSAP 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29203408
  3. Lau SR, Kriegbaum M. Medication non-adherence in the context of situated uncertainty: Moving beyond simple, dichotomous approaches. Research in social & administrative pharmacy : RSAP 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174075
  4. Ozdemir T, Sahin I, Avci, II et al. Assessment of factors related to statin non-adherence in patients with established coronary artery disease: A single-center observational study. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:723-730. http://www.ncbi.nlm.nih.gov/pubmed/?term=29226893

Atherosclerosis & Imaging

  1. Shioi A, Ikari Y. Plaque Calcification During Atherosclerosis Progression and Regression. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29238011
  2. Schwartz RG. What is this image? 2017: Image 4 result : Improvement of ischemia with statin therapy. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29196912
  3. Hu SG, Li H, Kang PF et al. [Effects of simvastatin on aortic vascular endothelial cell apoptosis and Bcl-2 protein expression in a rat model of atherosclerosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2017; 37:1456-1460. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180324
  4. Koga M, Toyoda K, Minematsu K et al. Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke). Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191850

Atorvastatin/Rosuvastatin

  1. Tripathi CB, Gupta N, Kumar P et al. omega-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260378
  2. Broniarek I, Jarmuszkiewicz W. Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria. Archives of biochemistry and biophysics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217137
  3. Aghazadeh J, Samadi Motlagh P, Salehpour F et al. Effects of Atorvastatin in Patients with Acute Spinal Cord Injury. Asian spine journal 2017; 11:903-907. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279745
  4. Prado Y, Arancibia A, Zambrano T, Salazar LA. Gender-specific Association between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients treated with Atorvastatin. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29178257
  5. Denisov IG, Baylon JL, Grinkova YV et al. Drug-drug interactions between Atorvastatin and Dronedarone mediated by monomeric CYP3A4. Biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200287
  6. Herrera-Gonzalez S, Martinez-Trevino DA, Aguirre-Garza M et al. Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population. Biomedical reports 2017; 7:579-584. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250329
  7. Zhang QH, Yin RX, Chen WX et al. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208769
  8. Kong Y, Cao XN, Zhang XH et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288170
  9. Joseph P, Lonn E, Bosch J et al. Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Can J Cardiol 2018; 34:38-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29275880
  10. Ye Y, Nylander S, Birnbaum Y. Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29185103
  11. Logue JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis. Case reports in oncology 2017; 10:954-957. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279698
  12. Nissen SE, Nicholls SJ. Results of the GLAGOV trial. Cleveland Clinic journal of medicine 2017; 84:e1-e5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29281604
  13. Oh J, Lee CJ, Kim DI et al. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243274
  14. Steen DL, Umez-Eronini AA, Guo J et al. The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283450
  15. McLean CC, Teft WA, Morse BL et al. Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29218707
  16. Kim CH, Han KA, Yu J et al. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-Treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223557
  17. Lewis SJ, Olufade T, Anzalone DA et al. LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current medical research and opinion 2017:1-16. http://www.ncbi.nlm.nih.gov/pubmed/?term=29271267
  18. Gruzdeva O, Uchasova E, Dyleva Y et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. Diabetes, metabolic syndrome and obesity : targets and therapy 2017; 10:481-489. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255368
  19. Gavazzoni M, Gorga E, Derosa G et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug design, development and therapy 2017; 11:3425-3434. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270001
  20. Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug design, development and therapy 2017; 11:3461-3469. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255347
  21. Bai X, Wang XP, He GD et al. Simultaneous Determination of Rosuvastatin, Rosuvastatin-5 S-lactone, and N-desmethyl Rosuvastatin in Human Plasma by UPLC-MS/MS and Its Application to Clinical Study. Drug research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29232752
  22. Oliveira CV, Grigoletto J, Canzian JM et al. Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy & behavior : E&B 2017; 78:109-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=29186698
  23. Morival C, Westerlynck R, Bouzille G et al. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255993
  24. Wang P, Luo L, Shen Q et al. Rosuvastatin improves myocardial Hypertrophy after hemodynamic Pressure overload via regulating the Crosstalk of Nrf2/ARE and TGF-beta/ Smads Pathways in Rat Heart. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29225188
  25. Zhang N, Zhang M, Liu RT et al. Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288118
  26. Cong L, Fu S, Zhang J et al. Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells. Experimental and therapeutic medicine 2018; 15:210-216. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250149
  27. Ren Y, Zhu H, Fan Z et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and therapeutic medicine 2017; 14:4942-4950. http://www.ncbi.nlm.nih.gov/pubmed/?term=29201198
  28. Takayama T, Hiro T, Yoda S et al. Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study). Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29209775
  29. Ishikawa Y, Itoh T, Satoh M et al. Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome. Int Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279527
  30. Weisshaar S, Litschauer B, Kerbel T, Wolzt M. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288055
  31. Talebpour Amiri F, Hamzeh M, Naeim RA et al. Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice. International journal of radiation biology 2017:1-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268056
  32. Temiz MZ, Yuruk E, Ertas K et al. Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study. International urology and nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197934
  33. Lawler PR, Akinkuolie AO, Harada P et al. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223956
  34. Andalib S, Molhemazar P, Danafar H. In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles. Journal of biomaterials applications 2017:885328217750821. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283039
  35. Yang B, Sun J, Yuan Y, Sun Z. Effects of atorvastatin on autophagy in skeletal muscles of diabetic rats. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29245171
  36. Bertl K, Steiner I, Pandis N et al. Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta-analysis of preclinical in vivo trials. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29211309
  37. Semenova AE, Sergienko IV. [Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease]. Kardiologiia 2017; 57:73-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=29276932
  38. Zhang JJ, Zhang YZ, Peng JJ et al. Atorvastatin exerts inhibitory effect on endothelial senescence in hyperlipidemic rats through a mechanism involving down-regulation of miR-21-5p/203a-3p. Mechanisms of ageing and development 2017; 169:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29248491
  39. Chen JH, Wu T, Yang LK et al. Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Mol Med Rep 2018; 17:1651-1659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257200
  40. Ahmed IS, El Hosary R, Hassan MA et al. Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Molecular pharmaceutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29232954
  41. Okoye I, Namdar A, Xu L et al. Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. Oncotarget 2017; 8:98215-98232. http://www.ncbi.nlm.nih.gov/pubmed/?term=29228684
  42. Tahta A, Izgi N, Onder TB et al. Assessment of the MRI and Behavioral Test Results in Focal Cerebral Ischemia Reperfusion Model in Rat after Separate and Combined Use of Mouse-Derived Neural Progenitor Cells, Human-Derived Neural Progenitor Cells and Atorvastatin. Turkish neurosurgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204982

Basic science

  1. Manickavasagam D, Novak K, Oyewumi MO. Therapeutic Delivery of Simvastatin Loaded in PLA-PEG Polymersomes Resulted in Amplification of Anti-inflammatory Effects in Activated Microglia. The AAPS journal 2017; 20:18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243172
  2. Tripathi CB, Gupta N, Kumar P et al. omega-3 Fatty Acid Synergized Novel Nanoemulsifying System for Rosuvastatin Delivery: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260378
  3. Haas MJ, Jurado-Flores M, Hammoud R et al. The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion From Human Coronary Artery Endothelial Cells. American journal of therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29232287
  4. Itoh H, Miura A, Matsui M et al. Knockout of the SREBP system increases production of the polyketide FR901512 in filamentous fungal sp. No. 14919 and lovastatin in Aspergillus terreus ATCC20542. Applied microbiology and biotechnology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270733
  5. Broniarek I, Jarmuszkiewicz W. Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria. Archives of biochemistry and biophysics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217137
  6. Zhang X, Jiang W, Liu Y et al. Human adipose-derived stem cells and simvastatin-functionalized biomimetic calcium phosphate to construct a novel tissue-engineered bone. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29175390
  7. Miller BR, Kung Y. Structural features and domain movements controlling substrate binding and cofactor specificity in class II HMG-CoA reductase. Biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224355
  8. Sun P, Hernandez-Guillamon M, Campos-Martorell M et al. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochim Biophys Acta 2017; 1864:542-553. http://www.ncbi.nlm.nih.gov/pubmed/?term=29175057
  9. Zhang W, Yang X, Chen Y et al. Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. Biochim Biophys Acta 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217477
  10. Leite M, Soares DG, Basso FG et al. Biostimulatory effects of simvastatin on MDPC-23 odontoblast-like cells. Brazilian oral research 2017; 31:e104. http://www.ncbi.nlm.nih.gov/pubmed/?term=29267665
  11. Yu R, Longo J, van Leeuwen JE et al. Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins. Cancer research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29229608
  12. Hao J, Chou J, Kuroda S et al. Injectable simvastatin gel for minimally invasive periosteal distraction: In vitro and in vivo studies in rat. Clinical oral implants research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250831
  13. Fathi HA, Allam A, Elsabahy M et al. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids and surfaces. B, Biointerfaces 2017; 162:236-245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197789
  14. Paskeviciute M, Petrikaite V. Differences of statin activity in 2D and 3D pancreatic cancer cell cultures. Drug design, development and therapy 2017; 11:3273-3280. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180851
  15. Cetkovic Z, Cvijic S, Vasiljevic D. In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems. Drug development and industrial pharmacy 2017:1-49. http://www.ncbi.nlm.nih.gov/pubmed/?term=29228833
  16. Oliveira CV, Grigoletto J, Canzian JM et al. Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy & behavior : E&B 2017; 78:109-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=29186698
  17. Wang P, Luo L, Shen Q et al. Rosuvastatin improves myocardial Hypertrophy after hemodynamic Pressure overload via regulating the Crosstalk of Nrf2/ARE and TGF-beta/ Smads Pathways in Rat Heart. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29225188
  18. Jin Y, Xu K, Chen Q et al. Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Experimental cell research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208461
  19. Cong L, Fu S, Zhang J et al. Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells. Experimental and therapeutic medicine 2018; 15:210-216. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250149
  20. Fang D, He Y, Luan Z. Simvastatin augments activation of liver regeneration through attenuating transforming growth factor-beta1 induced-apoptosis in obstructive jaundice rats. Experimental and therapeutic medicine 2017; 14:4839-4845. http://www.ncbi.nlm.nih.gov/pubmed/?term=29201188
  21. Corso CR, Martins DF, Borges SC et al. Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats. Inflammopharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29188473
  22. Choi HW, Shin PG, Lee JH et al. Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-kappaB and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages. International journal of molecular medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29207042
  23. Chen MC, Tsai YC, Tseng JH et al. Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29236027
  24. Talebpour Amiri F, Hamzeh M, Naeim RA et al. Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice. International journal of radiation biology 2017:1-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268056
  25. Temiz MZ, Yuruk E, Ertas K et al. Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study. International urology and nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197934
  26. Andalib S, Molhemazar P, Danafar H. In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles. Journal of biomaterials applications 2017:885328217750821. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283039
  27. Hasegawa Y, Hori M, Nakagami T et al. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type II diabetes mellitus treated with statins. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217412
  28. Yang B, Sun J, Yuan Y, Sun Z. Effects of atorvastatin on autophagy in skeletal muscles of diabetic rats. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29245171
  29. Raffoul-Orozco AK, Avila-Gonzalez AE, Rodriguez-Razon CM et al. Combination effect naringin and pravastatin in lipid profile and glucose in obese rats. Life sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197498
  30. Gbelcova H, Rimpelova S, Knejzlik Z et al. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Lipids Health Dis 2017; 16:250. http://www.ncbi.nlm.nih.gov/pubmed/?term=29262834
  31. Zhang JJ, Zhang YZ, Peng JJ et al. Atorvastatin exerts inhibitory effect on endothelial senescence in hyperlipidemic rats through a mechanism involving down-regulation of miR-21-5p/203a-3p. Mechanisms of ageing and development 2017; 169:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29248491
  32. Liu Y, Tu X, Xu Q et al. Engineered monoculture and co-culture of methylotrophic yeast for de novo production of monacolin J and lovastatin from methanol. Metabolic engineering 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258964
  33. Chen JH, Wu T, Yang LK et al. Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Mol Med Rep 2018; 17:1651-1659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257200
  34. Liu W, Zhao Y, Zhang X, Ji J. Simvastatin ameliorates cognitive impairments via inhibition of oxidative stressinduced apoptosis of hippocampal cells through the ERK/AKT signaling pathway in a rat model of senile dementia. Mol Med Rep 2018; 17:1885-1892. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257256
  35. Zhu S, Wang J, Wang X, Zhao J. Protection against monocrotaline-induced pulmonary arterial hypertension and caveolin-1 downregulation by fluvastatin in rats. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29286128
  36. Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C et al. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224179
  37. Ahmed IS, El Hosary R, Hassan MA et al. Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution. Molecular pharmaceutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29232954
  38. Awad E, Othman EM, Stopper H. Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro. Molecules (Basel, Switzerland) 2017; 22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29231877
  39. Hu SG, Li H, Kang PF et al. [Effects of simvastatin on aortic vascular endothelial cell apoptosis and Bcl-2 protein expression in a rat model of atherosclerosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2017; 37:1456-1460. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180324
  40. Lv ZH, Phuong TA, Jin SJ et al. Protection by simvastatin on hyperglycemia-induced endothelial dysfunction through inhibiting NLRP3 inflammasomes. Oncotarget 2017; 8:91291-91305. http://www.ncbi.nlm.nih.gov/pubmed/?term=29207644
  41. Okoye I, Namdar A, Xu L et al. Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. Oncotarget 2017; 8:98215-98232. http://www.ncbi.nlm.nih.gov/pubmed/?term=29228684
  42. Fong Soe Khioe R, Skedgel C, Hart A et al. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29210031
  43. Sadighara M, Joktaji JP, Hajhashemi V, Minaiyan M. Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Research in pharmaceutical sciences 2017; 12:434-443. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204172
  44. Alhazmi HA, Alnami AM, Arishi MAA et al. A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations. Scientia pharmaceutica 2017; 86. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257120
  45. Vassilieva EV, Wang S, Li S et al. Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine. Scientific reports 2017; 7:17855. http://www.ncbi.nlm.nih.gov/pubmed/?term=29259264
  46. Tahta A, Izgi N, Onder TB et al. Assessment of the MRI and Behavioral Test Results in Focal Cerebral Ischemia Reperfusion Model in Rat after Separate and Combined Use of Mouse-Derived Neural Progenitor Cells, Human-Derived Neural Progenitor Cells and Atorvastatin. Turkish neurosurgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204982

Cancer

  1. Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. Breast cancer (Dove Medical Press) 2017; 9:559-565. http://www.ncbi.nlm.nih.gov/pubmed/?term=29238220
  2. Dawe DE, Mahmud S. Biologic and epidemiologic evidence assessing if statins prevent prostate cancer. The Canadian journal of urology 2017; 24:9081-9088. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260632
  3. Yu R, Longo J, van Leeuwen JE et al. Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins. Cancer research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29229608
  4. Paskeviciute M, Petrikaite V. Differences of statin activity in 2D and 3D pancreatic cancer cell cultures. Drug design, development and therapy 2017; 11:3273-3280. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180851
  5. Jin Y, Xu K, Chen Q et al. Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Experimental cell research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208461
  6. Fransgaard T, Thygesen LC, Gogenur I. Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. International journal of colorectal disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270783
  7. Chen MC, Tsai YC, Tseng JH et al. Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29236027
  8. Lin BM, Li WQ, Cho E et al. Statin Use and Risk of Skin Cancer. Journal of the American Academy of Dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208416
  9. Kapoor S. Neoplastic growth-restricting effects of fluvastatin in systemic malignancies. J Surg Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29183627
  10. Gbelcova H, Rimpelova S, Knejzlik Z et al. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Lipids Health Dis 2017; 16:250. http://www.ncbi.nlm.nih.gov/pubmed/?term=29262834
  11. Fong Soe Khioe R, Skedgel C, Hart A et al. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29210031
  12. Couttenier A, Lacroix O, Vaes E et al. Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLoS One 2017; 12:e0189233. http://www.ncbi.nlm.nih.gov/pubmed/?term=29261726
  13. Jamnagerwalla J, Howard LE, Allott EH et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29282360
  14. Iannelli F, Lombardi R, Milone MR et al. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. Recent patents on anti-cancer drug discovery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29189178

Children

  1. Rocha VZ, Santos RD. Safety of statin treatment in children with familial hypercholesterolemia: Filling the gaps. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29287917

Cost-effectiveness

  1. Fong Soe Khioe R, Skedgel C, Hart A et al. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29210031

CVD

  1. Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29263150
  2. Gruzdeva O, Uchasova E, Dyleva Y et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. Diabetes, metabolic syndrome and obesity : targets and therapy 2017; 10:481-489. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255368
  3. Gavazzoni M, Gorga E, Derosa G et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug design, development and therapy 2017; 11:3425-3434. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270001
  4. Delles C, Rankin NJ, Boachie C et al. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. European journal of heart failure 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29226610
  5. Nakahashi T, Tada H, Sakata K et al. Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288404
  6. Huang CY, Lin TT, Yang YH et al. Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with rheumatoid arthritis. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174015

Endothelium/inflammation

  1. Haas MJ, Jurado-Flores M, Hammoud R et al. The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion From Human Coronary Artery Endothelial Cells. American journal of therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29232287
  2. Zhang N, Zhang M, Liu RT et al. Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288118
  3. Ren Y, Zhu H, Fan Z et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and therapeutic medicine 2017; 14:4942-4950. http://www.ncbi.nlm.nih.gov/pubmed/?term=29201198
  4. Zhou X, Chen J, Wang C, Wu L. Anti-inflammatory effects of Simvastatin in patients with acute intracerebral hemorrhage in an intensive care unit. Experimental and therapeutic medicine 2017; 14:6193-6200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29285177
  5. Takayama T, Hiro T, Yoda S et al. Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study). Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29209775
  6. Weisshaar S, Litschauer B, Kerbel T, Wolzt M. Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288055
  7. Choi HW, Shin PG, Lee JH et al. Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-kappaB and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages. International journal of molecular medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29207042
  8. Andalib S, Molhemazar P, Danafar H. In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles. Journal of biomaterials applications 2017:885328217750821. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283039
  9. Toutouzas K, Skoumas J, Koutagiar I et al. Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174439
  10. Lv ZH, Phuong TA, Jin SJ et al. Protection by simvastatin on hyperglycemia-induced endothelial dysfunction through inhibiting NLRP3 inflammasomes. Oncotarget 2017; 8:91291-91305. http://www.ncbi.nlm.nih.gov/pubmed/?term=29207644

Ethnicity

  1. Shek AB, Kurbanov RD, Abdullaeva GJ et al. Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. Archives of medical sciences. Atherosclerotic diseases 2017; 2:e68-e75. http://www.ncbi.nlm.nih.gov/pubmed/?term=29242847
  2. Kimando MW, Otieno FCF, Ogola EN, Mutai K. Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. BMC endocrine disorders 2017; 17:73. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191193
  3. Nagar SP, Rane PP, Fox KM et al. Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29276211
  4. Oh J, Lee CJ, Kim DI et al. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243274
  5. Zuo HJ, Wang WH, Deng LQ, Su JL. Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension : JASH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29289467

FH

  1. Oh J, Lee CJ, Kim DI et al. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243274
  2. Faggiano P, Pirillo A, Griffo R et al. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. Int J Cardiol 2018; 252:193-198. http://www.ncbi.nlm.nih.gov/pubmed/?term=29249427
  3. Humphries SE, Cooper J, Dale P, Ramaswami U. The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208363
  4. Ma Y, Gong Y, Garg A, Zhou H. Compound heterozygous familial hypercholesterolemia in a Chinese boy with a de novo and transmitted low-density lipoprotein receptor mutation. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29233637
  5. Toutouzas K, Skoumas J, Koutagiar I et al. Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174439 

Genetics

  1. Shek AB, Kurbanov RD, Abdullaeva GJ et al. Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. Archives of medical sciences. Atherosclerotic diseases 2017; 2:e68-e75. http://www.ncbi.nlm.nih.gov/pubmed/?term=29242847
  2. Prado Y, Arancibia A, Zambrano T, Salazar LA. Gender-specific Association between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients treated with Atorvastatin. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29178257
  3. Herrera-Gonzalez S, Martinez-Trevino DA, Aguirre-Garza M et al. Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population. Biomedical reports 2017; 7:579-584. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250329
  4. Zhang QH, Yin RX, Chen WX et al. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208769
  5. Sumi A, Nakamura U, Iwase M et al. The gene-treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry. BMC medical genetics 2017; 18:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29233102
  6. Braillon A. Letter by Braillon Regarding Article, "Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting". Circulation 2017; 136:2204-2205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180501
  7. Hubacek JA, Adamkova V, Zlatohlavek L et al. COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. Drug Metab Pers Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257754
  8. Christen T, Trompet S, Noordam R et al. Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174438
  9. MA VW, Kaleta EJ, Bryant SC et al. Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29210320

Guidelines

  1. Flannery LD, Fahed AC, DeFaria Yeh D et al. Frequency of Guideline-Based Statin Therapy in Adults With Congenital Heart Disease. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268935
  2. Gurgle HE, Schauerhamer MB, Rodriguez SA, McAdam-Marx C. Impact of statin guidelines on statin utilization and costs in an employer-based primary care clinic. The American journal of managed care 2017; 23:e387-e393. http://www.ncbi.nlm.nih.gov/pubmed/?term=29261246
  3. Marz W, Dippel FW, Theobald K et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 2017; 268:99-107. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197254
  4. Kimando MW, Otieno FCF, Ogola EN, Mutai K. Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. BMC endocrine disorders 2017; 17:73. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191193
  5. Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29182745
  6. Bucheit JD, Helsing H, Nadpara P et al. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29277495
  7. Menzin J, Aggarwal J, Boatman B et al. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of managed care & specialty pharmacy 2017; 23:1270-1276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172973
  8. Dyrbus K, Osadnik T, Desperak P et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258913

LDL- related parameters

  1. Bauters C, Tricot O, Lemesle G et al. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. Arch Cardiovasc Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29198936
  2. Chang JJ, Katsanos AH, Khorchid Y et al. Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage. Atherosclerosis 2017; 269:14-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29253643
  3. Kimando MW, Otieno FCF, Ogola EN, Mutai K. Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. BMC endocrine disorders 2017; 17:73. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191193
  4. Bakke A, Cooper JG, Thue G et al. Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening. BMJ open diabetes research & care 2017; 5:e000459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29177051
  5. Ho JE. Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of Statins. Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29237684
  6. Kofink D, Eppinga RN, van Gilst WH et al. Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29237679
  7. Steen DL, Umez-Eronini AA, Guo J et al. The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283450
  8. Gitt AK, Lautsch D, Ferrieres J et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data in brief 2018; 16:369-375. http://www.ncbi.nlm.nih.gov/pubmed/?term=29234694
  9. Gavazzoni M, Gorga E, Derosa G et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug design, development and therapy 2017; 11:3425-3434. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270001
  10. Graham I, Shear C, De Graeff P et al. New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk. European heart journal. Cardiovascular pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29194462
  11. Menzin J, Aggarwal J, Boatman B et al. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of managed care & specialty pharmacy 2017; 23:1270-1276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172973
  12. Wolffenbuttel BHR, Slagter SN, van Waateringe RP et al. Unfavourable blood pressure and LDL-cholesterol levels in obese non-diabetic individuals. The Netherlands journal of medicine 2017; 75:399-411. http://www.ncbi.nlm.nih.gov/pubmed/?term=29219813
  13. Dyrbus K, Osadnik T, Desperak P et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258913

Lifestyle

  1. Huang BT, Huang FY, Pu XB et al. No modifying effect of nutritional status on statins therapy in relation to all-cause death in older patients with coronary artery disease. Aging clinical and experimental research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260400
  2. McLean CC, Teft WA, Morse BL et al. Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29218707
  3. Kawai H, Ihara K, Kera T et al. Association between statin use and physical function among community-dwelling older Japanese adults. Geriatrics & gerontology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29278297

Meta-analyses

  1. Rossignol M, Labrecque M, Cauchon M et al. Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality. Family practice 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29267889
  2. Bertl K, Steiner I, Pandis N et al. Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta-analysis of preclinical in vivo trials. Journal of periodontal research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29211309

Metabolic Syndrome - Diabetes

  1. Scicali R, Di Pino A, Ferrara V et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260404
  2. Bakke A, Cooper JG, Thue G et al. Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening. BMJ open diabetes research & care 2017; 5:e000459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29177051
  3. Kovarnik T, Chen Z, Mintz GS et al. Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. Cardiovascular diabetology 2017; 16:156. http://www.ncbi.nlm.nih.gov/pubmed/?term=29212544
  4. Vavlukis M, Kedev S. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283060
  5. Zuo HJ, Wang WH, Deng LQ, Su JL. Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension : JASH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29289467
  6. Hasegawa Y, Hori M, Nakagami T et al. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type II diabetes mellitus treated with statins. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217412
  7. Gurgel MHC, Montenegro Junior RM, Melo Ponte CM et al. Metabolic syndrome, diabetes and inadequate lifestyle in first-degree relatives of acute myocardial infarction survivors younger than 45 years old. Lipids Health Dis 2017; 16:224. http://www.ncbi.nlm.nih.gov/pubmed/?term=29179759
  8. Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C et al. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224179
  9. Awad E, Othman EM, Stopper H. Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro. Molecules (Basel, Switzerland) 2017; 22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29231877
  10. Abbasalizadeh F, Saleh P, Dousti R et al. Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study. Nigerian medical journal : journal of the Nigeria Medical Association 2017; 58:63-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29269983

New Treatments

  1. Scicali R, Di Pino A, Ferrara V et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260404
  2. Stoekenbroek RM, Hartgers ML, Rutte R et al. PCSK9 inhibitors in clinical practice: Delivering on the promise? Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29254691
  3. Vavlukis M, Kedev S. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283060
  4. Harvey PD, Sabbagh MN, Harrison JE et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29186504
  5. Graham I, Shear C, De Graeff P et al. New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk. European heart journal. Cardiovascular pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29194462
  6. Cicero AFG, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29231064
  7. Sisson EM, Pamulapati L, Bucheit JD et al. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29266309

PAD and statins

  1. de Grijs D, Teixeira P, Katz S. The association of statin therapy with the primary patency of femoral and popliteal artery stents. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224939

Pleiotropic effects of statins

  1. Zhang X, Jiang W, Liu Y et al. Human adipose-derived stem cells and simvastatin-functionalized biomimetic calcium phosphate to construct a novel tissue-engineered bone. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29175390
  2. Sun P, Hernandez-Guillamon M, Campos-Martorell M et al. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochim Biophys Acta 2017; 1864:542-553. http://www.ncbi.nlm.nih.gov/pubmed/?term=29175057
  3. Zhang W, Yang X, Chen Y et al. Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. Biochim Biophys Acta 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217477
  4. Kong Y, Cao XN, Zhang XH et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288170
  5. Leite M, Soares DG, Basso FG et al. Biostimulatory effects of simvastatin on MDPC-23 odontoblast-like cells. Brazilian oral research 2017; 31:e104. http://www.ncbi.nlm.nih.gov/pubmed/?term=29267665
  6. Joseph P, Lonn E, Bosch J et al. Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Can J Cardiol 2018; 34:38-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29275880
  7. Hao J, Chou J, Kuroda S et al. Injectable simvastatin gel for minimally invasive periosteal distraction: In vitro and in vivo studies in rat. Clinical oral implants research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250831
  8. Oliveira CV, Grigoletto J, Canzian JM et al. Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy & behavior : E&B 2017; 78:109-117. http://www.ncbi.nlm.nih.gov/pubmed/?term=29186698
  9. Wang P, Luo L, Shen Q et al. Rosuvastatin improves myocardial Hypertrophy after hemodynamic Pressure overload via regulating the Crosstalk of Nrf2/ARE and TGF-beta/ Smads Pathways in Rat Heart. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29225188
  10. Fang D, He Y, Luan Z. Simvastatin augments activation of liver regeneration through attenuating transforming growth factor-beta1 induced-apoptosis in obstructive jaundice rats. Experimental and therapeutic medicine 2017; 14:4839-4845. http://www.ncbi.nlm.nih.gov/pubmed/?term=29201188
  11. Zhou X, Chen J, Wang C, Wu L. Anti-inflammatory effects of Simvastatin in patients with acute intracerebral hemorrhage in an intensive care unit. Experimental and therapeutic medicine 2017; 14:6193-6200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29285177
  12. Seyam E, Al Gelany S, Abd Al Ghaney A et al. Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258367
  13. Corso CR, Martins DF, Borges SC et al. Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats. Inflammopharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29188473
  14. Talebpour Amiri F, Hamzeh M, Naeim RA et al. Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice. International journal of radiation biology 2017:1-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268056
  15. Zhang C. Does Statin Reloading Before Cardiac Surgery Improve Postoperative Outcomes? Journal of cardiothoracic and vascular anesthesia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29203297
  16. Liu W, Zhao Y, Zhang X, Ji J. Simvastatin ameliorates cognitive impairments via inhibition of oxidative stressinduced apoptosis of hippocampal cells through the ERK/AKT signaling pathway in a rat model of senile dementia. Mol Med Rep 2018; 17:1885-1892. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257256
  17. Zhu S, Wang J, Wang X, Zhao J. Protection against monocrotaline-induced pulmonary arterial hypertension and caveolin-1 downregulation by fluvastatin in rats. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29286128
  18. Whigham B, Oddone EZ, Woolson S et al. The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis. Ophthalmic epidemiology 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172840
  19. Han N, Han SH, Song YK et al. Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. Therapeutics and clinical risk management 2017; 13:1513-1520. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200861  

Primary Prevention

  1. Bakke A, Cooper JG, Thue G et al. Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening. BMJ open diabetes research & care 2017; 5:e000459. http://www.ncbi.nlm.nih.gov/pubmed/?term=29177051
  2. Braillon A. Letter by Braillon Regarding Article, "Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting". Circulation 2017; 136:2204-2205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29180501
  3. Garcia-Gil M, Comas-Cufi M, Blanch J et al. Effectiveness of statins as primary prevention in people with different cardiovascular risk: A population-based cohort study. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29194590
  4. Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29182745
  5. Rossignol M, Labrecque M, Cauchon M et al. Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality. Family practice 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29267889

Registry data

  1. Huang BT, Huang FY, Pu XB et al. No modifying effect of nutritional status on statins therapy in relation to all-cause death in older patients with coronary artery disease. Aging clinical and experimental research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260400
  2. Go AS, Fan D, Sung SH et al. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. Am Heart J 2017; 194:25-38. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223433
  3. Flannery LD, Fahed AC, DeFaria Yeh D et al. Frequency of Guideline-Based Statin Therapy in Adults With Congenital Heart Disease. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268935
  4. Bauters C, Tricot O, Lemesle G et al. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. Arch Cardiovasc Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29198936
  5. Chang JJ, Katsanos AH, Khorchid Y et al. Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage. Atherosclerosis 2017; 269:14-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29253643
  6. Marz W, Dippel FW, Theobald K et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 2017; 268:99-107. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197254
  7. Stoekenbroek RM, Hartgers ML, Rutte R et al. PCSK9 inhibitors in clinical practice: Delivering on the promise? Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29254691
  8. Sturlaugsdottir R, Aspelund T, Bjornsdottir G et al. Predictors of carotid plaque progression over a 4-year follow-up in the Reykjavik REFINE-study. Atherosclerosis 2017; 269:57-62. http://www.ncbi.nlm.nih.gov/pubmed/?term=29274849
  9. Nagar SP, Rane PP, Fox KM et al. Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29276211
  10. Garcia-Gil M, Comas-Cufi M, Blanch J et al. Effectiveness of statins as primary prevention in people with different cardiovascular risk: A population-based cohort study. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29194590
  11. Gitt AK, Lautsch D, Ferrieres J et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world. Data in brief 2018; 16:369-375. http://www.ncbi.nlm.nih.gov/pubmed/?term=29234694
  12. Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29182745
  13. Zhou X, Chen J, Wang C, Wu L. Anti-inflammatory effects of Simvastatin in patients with acute intracerebral hemorrhage in an intensive care unit. Experimental and therapeutic medicine 2017; 14:6193-6200. http://www.ncbi.nlm.nih.gov/pubmed/?term=29285177
  14. Kawai H, Ihara K, Kera T et al. Association between statin use and physical function among community-dwelling older Japanese adults. Geriatrics & gerontology international 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29278297
  15. Nakahashi T, Tada H, Sakata K et al. Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288404
  16. Faggiano P, Pirillo A, Griffo R et al. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. Int J Cardiol 2018; 252:193-198. http://www.ncbi.nlm.nih.gov/pubmed/?term=29249427
  17. Huang CY, Lin TT, Yang YH et al. Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with rheumatoid arthritis. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29174015
  18. Fransgaard T, Thygesen LC, Gogenur I. Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. International journal of colorectal disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270783
  19. Lin BM, Li WQ, Cho E et al. Statin Use and Risk of Skin Cancer. Journal of the American Academy of Dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208416
  20. Zuo HJ, Wang WH, Deng LQ, Su JL. Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension : JASH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29289467
  21. Humphries SE, Cooper J, Dale P, Ramaswami U. The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208363
  22. Jacobson TA, Khan A, Maki KC et al. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29239815
  23. Menzin J, Aggarwal J, Boatman B et al. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. Journal of managed care & specialty pharmacy 2017; 23:1270-1276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172973
  24. de Grijs D, Teixeira P, Katz S. The association of statin therapy with the primary patency of femoral and popliteal artery stents. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224939
  25. Whigham B, Oddone EZ, Woolson S et al. The influence of oral statin medications on progression of glaucomatous visual field loss: A propensity score analysis. Ophthalmic epidemiology 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29172840
  26. Dyrbus K, Osadnik T, Desperak P et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacol Res 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258913
  27. Couttenier A, Lacroix O, Vaes E et al. Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLoS One 2017; 12:e0189233. http://www.ncbi.nlm.nih.gov/pubmed/?term=29261726
  28. Leonard CE, Brensinger CM, Bilker WB et al. Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Scientific reports 2017; 7:18037. http://www.ncbi.nlm.nih.gov/pubmed/?term=29269848

Renal Disease

  1. Talebpour Amiri F, Hamzeh M, Naeim RA et al. Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice. International journal of radiation biology 2017:1-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29268056
  2. Temiz MZ, Yuruk E, Ertas K et al. Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study. International urology and nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197934
  3. Smith LE, Smith DK, Blume JD et al. High-Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223955
  4. Abbasalizadeh F, Saleh P, Dousti R et al. Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study. Nigerian medical journal : journal of the Nigeria Medical Association 2017; 58:63-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29269983
  5. Han N, Han SH, Song YK et al. Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. Therapeutics and clinical risk management 2017; 13:1513-1520. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200861

Reviews

  1. Scicali R, Di Pino A, Ferrara V et al. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260404
  2. Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. Breast cancer (Dove Medical Press) 2017; 9:559-565. http://www.ncbi.nlm.nih.gov/pubmed/?term=29238220
  3. Dawe DE, Mahmud S. Biologic and epidemiologic evidence assessing if statins prevent prostate cancer. The Canadian journal of urology 2017; 24:9081-9088. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260632
  4. Vavlukis M, Kedev S. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283060
  5. Graham I, Shear C, De Graeff P et al. New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk. European heart journal. Cardiovascular pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29194462
  6. Shioi A, Ikari Y. Plaque Calcification During Atherosclerosis Progression and Regression. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29238011
  7. Zhang C. Does Statin Reloading Before Cardiac Surgery Improve Postoperative Outcomes? Journal of cardiothoracic and vascular anesthesia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29203297
  8. Bucheit JD, Helsing H, Nadpara P et al. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29277495
  9. Rocha VZ, Santos RD. Safety of statin treatment in children with familial hypercholesterolemia: Filling the gaps. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29287917
  10. Skeldon SC, Cheng L, Morgan SG et al. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study. The journal of sexual medicine 2017; 14:1597-1605. http://www.ncbi.nlm.nih.gov/pubmed/?term=29198514
  11. Sisson EM, Pamulapati L, Bucheit JD et al. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29266309
  12. Iannelli F, Lombardi R, Milone MR et al. Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. Recent patents on anti-cancer drug discovery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29189178

Safety and side effects

  1. Bataillard M, Beyens MN, Mounier G et al. Muscle Damage Due to Fusidic Acid-Statin Interaction: Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports. American journal of therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29189310
  2. Broniarek I, Jarmuszkiewicz W. Atorvastatin affects negatively respiratory function of isolated endothelial mitochondria. Archives of biochemistry and biophysics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29217137
  3. Shek AB, Kurbanov RD, Abdullaeva GJ et al. Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. Archives of medical sciences. Atherosclerotic diseases 2017; 2:e68-e75. http://www.ncbi.nlm.nih.gov/pubmed/?term=29242847
  4. Denisov IG, Baylon JL, Grinkova YV et al. Drug-drug interactions between Atorvastatin and Dronedarone mediated by monomeric CYP3A4. Biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200287
  5. Sumi A, Nakamura U, Iwase M et al. The gene-treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry. BMC medical genetics 2017; 18:146. http://www.ncbi.nlm.nih.gov/pubmed/?term=29233102
  6. Herrett E, Williamson E, Beaumont D et al. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open 2017; 7:e016604. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197834
  7. Ye Y, Nylander S, Birnbaum Y. Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice. Cardiovasc Drugs Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29185103
  8. Logue JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis. Case reports in oncology 2017; 10:954-957. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279698
  9. Barnett S, Ogungbenro K, Menochet K et al. Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modelling and simulation. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243231
  10. McLean CC, Teft WA, Morse BL et al. Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol. Clinical pharmacology and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29218707
  11. Kellick K. Organic Ion Transporters and Statin Drug Interactions. Curr Atheroscler Rep 2017; 19:65. http://www.ncbi.nlm.nih.gov/pubmed/?term=29177971
  12. Gruzdeva O, Uchasova E, Dyleva Y et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. Diabetes, metabolic syndrome and obesity : targets and therapy 2017; 10:481-489. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255368
  13. Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug design, development and therapy 2017; 11:3461-3469. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255347
  14. Hubacek JA, Adamkova V, Zlatohlavek L et al. COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. Drug Metab Pers Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257754
  15. Harvey PD, Sabbagh MN, Harrison JE et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29186504
  16. Guercio V, Turati F, Bosetti C et al. Bladder cancer risk in users of selected drugs for cardiovascular disease prevention. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29280915
  17. Morival C, Westerlynck R, Bouzille G et al. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255993
  18. Cicero AFG, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol 2017:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29231064
  19. Lin BM, Li WQ, Cho E et al. Statin Use and Risk of Skin Cancer. Journal of the American Academy of Dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208416
  20. Jacobson TA, Khan A, Maki KC et al. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29239815
  21. Yang B, Sun J, Yuan Y, Sun Z. Effects of atorvastatin on autophagy in skeletal muscles of diabetic rats. Journal of diabetes investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29245171
  22. Chemello RML, Benvegnu AM, Dallazem LND, Chemello D. Aggressive and fatal statin-induced dermatomyositis: a case report. Oxford medical case reports 2017; 2017:omx063. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255614
  23. MA VW, Kaleta EJ, Bryant SC et al. Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29210320
  24. Sadighara M, Joktaji JP, Hajhashemi V, Minaiyan M. Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Research in pharmaceutical sciences 2017; 12:434-443. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204172
  25. Vassilieva EV, Wang S, Li S et al. Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine. Scientific reports 2017; 7:17855. http://www.ncbi.nlm.nih.gov/pubmed/?term=29259264
  26. Han N, Han SH, Song YK et al. Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation. Therapeutics and clinical risk management 2017; 13:1513-1520. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200861

Stroke and CNS

  1. Chang JJ, Katsanos AH, Khorchid Y et al. Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage. Atherosclerosis 2017; 269:14-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29253643
  2. Sun P, Hernandez-Guillamon M, Campos-Martorell M et al. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochim Biophys Acta 2017; 1864:542-553. http://www.ncbi.nlm.nih.gov/pubmed/?term=29175057
  3. Chen JH, Wu T, Yang LK et al. Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Mol Med Rep 2018; 17:1651-1659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257200
  4. Liu W, Zhao Y, Zhang X, Ji J. Simvastatin ameliorates cognitive impairments via inhibition of oxidative stressinduced apoptosis of hippocampal cells through the ERK/AKT signaling pathway in a rat model of senile dementia. Mol Med Rep 2018; 17:1885-1892. http://www.ncbi.nlm.nih.gov/pubmed/?term=29257256
  5. Infante-Garcia C, Ramos-Rodriguez JJ, Hierro-Bujalance C et al. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224179
  6. Endres M, Nolte CH, Scheitz JF. Statin Treatment in Patients With Intracerebral Hemorrhage. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191849
  7. Tahta A, Izgi N, Onder TB et al. Assessment of the MRI and Behavioral Test Results in Focal Cerebral Ischemia Reperfusion Model in Rat after Separate and Combined Use of Mouse-Derived Neural Progenitor Cells, Human-Derived Neural Progenitor Cells and Atorvastatin. Turkish neurosurgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29204982

Triglycerides/HDL

  1. Prado Y, Arancibia A, Zambrano T, Salazar LA. Gender-specific Association between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients treated with Atorvastatin. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29178257
  2. Ho JE. Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of Statins. Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29237684
  3. Kofink D, Eppinga RN, van Gilst WH et al. Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29237679
  4. Kim CH, Han KA, Yu J et al. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-Treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223557
  5. Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29182745
  6. Lawler PR, Akinkuolie AO, Harada P et al. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223956
  7. Smith LE, Smith DK, Blume JD et al. High-Density Lipoprotein Cholesterol Concentration and Acute Kidney Injury After Cardiac Surgery. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223955

Trials

  1. Issa OM, Roberts R, Mark DB et al. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). Am Heart J 2018; 195:70-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=29224648
  2. Aghazadeh J, Samadi Motlagh P, Salehpour F et al. Effects of Atorvastatin in Patients with Acute Spinal Cord Injury. Asian spine journal 2017; 11:903-907. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279745
  3. Hua P, Liu J, Tao J et al. Efficacy and Mechanism of Preoperative Simvastatin Therapy on Myocardial Protection after Extracorporeal Circulation. BioMed research international 2017; 2017:6082430. http://www.ncbi.nlm.nih.gov/pubmed/?term=29250545
  4. Zhang QH, Yin RX, Chen WX et al. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29208769
  5. Kong Y, Cao XN, Zhang XH et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288170
  6. Herrett E, Williamson E, Beaumont D et al. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open 2017; 7:e016604. http://www.ncbi.nlm.nih.gov/pubmed/?term=29197834
  7. Joseph P, Lonn E, Bosch J et al. Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Can J Cardiol 2018; 34:38-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29275880
  8. Kovarnik T, Chen Z, Mintz GS et al. Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. Cardiovascular diabetology 2017; 16:156. http://www.ncbi.nlm.nih.gov/pubmed/?term=29212544
  9. Kofink D, Eppinga RN, van Gilst WH et al. Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial). Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29237679
  10. Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29263150
  11. Oh J, Lee CJ, Kim DI et al. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29243274
  12. Steen DL, Umez-Eronini AA, Guo J et al. The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29283450
  13. Kim CH, Han KA, Yu J et al. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-Treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223557
  14. Lewis SJ, Olufade T, Anzalone DA et al. LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current medical research and opinion 2017:1-16. http://www.ncbi.nlm.nih.gov/pubmed/?term=29271267
  15. Gavazzoni M, Gorga E, Derosa G et al. High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug design, development and therapy 2017; 11:3425-3434. http://www.ncbi.nlm.nih.gov/pubmed/?term=29270001
  16. Kim CH, An H, Kim SH, Shin D. Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. Drug design, development and therapy 2017; 11:3461-3469. http://www.ncbi.nlm.nih.gov/pubmed/?term=29255347
  17. Delles C, Rankin NJ, Boachie C et al. Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. European journal of heart failure 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29226610
  18. Zhang N, Zhang M, Liu RT et al. Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29288118
  19. Ren Y, Zhu H, Fan Z et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and therapeutic medicine 2017; 14:4942-4950. http://www.ncbi.nlm.nih.gov/pubmed/?term=29201198
  20. Seyam E, Al Gelany S, Abd Al Ghaney A et al. Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258367
  21. Takayama T, Hiro T, Yoda S et al. Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study). Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29209775
  22. Ishikawa Y, Itoh T, Satoh M et al. Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome. Int Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29279527
  23. Lawler PR, Akinkuolie AO, Harada P et al. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29223956
  24. Danaei G, Garcia Rodriguez LA, Cantero OF et al. Electronic medical records can be used to emulate target trials of sustained treatment strategies. J Clin Epidemiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29203418
  25. Gbelcova H, Rimpelova S, Knejzlik Z et al. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Lipids Health Dis 2017; 16:250. http://www.ncbi.nlm.nih.gov/pubmed/?term=29262834
  26. Naiqiong W, Liansheng W, Zhanying H et al. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Medical science monitor : international medical journal of experimental and clinical research 2017; 23:5760-5766. http://www.ncbi.nlm.nih.gov/pubmed/?term=29200411
  27. Abbasalizadeh F, Saleh P, Dousti R et al. Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study. Nigerian medical journal : journal of the Nigeria Medical Association 2017; 58:63-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29269983
  28. Jamnagerwalla J, Howard LE, Allott EH et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29282360
  29. Kriegbaum M, Lau SR. Medication non-adherence and uncertainty: Information-seeking and processing in the Danish LIFESTAT survey. Research in social & administrative pharmacy : RSAP 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29203408
  30. Koga M, Toyoda K, Minematsu K et al. Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke). Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29191850
  31. Fonseca FAH, Izar MC, Maugeri IML et al. Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial. Trials 2017; 18:601. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258572

Women and elderly

  1. Huang BT, Huang FY, Pu XB et al. No modifying effect of nutritional status on statins therapy in relation to all-cause death in older patients with coronary artery disease. Aging clinical and experimental research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29260400
  2. Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. American journal of obstetrics and gynecology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29229321
  3. Llobet Vila L, Manresa Dominguez JM, Carmona Segado JM et al. [Facing a dilemma in elderly complex and vulnerable patients: to stop or not to stop prevention?]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29221946
  4. Seyam E, Al Gelany S, Abd Al Ghaney A et al. Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29258367
 
 
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.